Dr. Hugh Sampson presents Epicutaneous Immunotherapy for Food Allergy at the World Allergy Organization Conference

BAGNEUX, France, Dec. 13, 2013 — DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, announced today the presentation of “Epicutaneous Immunotherapy for Food Allergy” at a meeting of the World Allergy Organization by Dr. Hugh Sampson, Kurt Hirschhorn Professor of Pediatrics, Director of the Jaffe Food Allergy Institute and Dean of Translational Biomedical Science at The Mount Sinai Medical Center in New York (USA). During his oral presentation, Dr. Sampson compared Epicutaneous Immunotherapy (EPIT™) to Oral Immunotherapy (OIT) and Sublingual Immunotherapy (SLIT), describing the basic immunologic changes associated with EPIT and analyzing immunologic parameters indicative of successful immunotherapy.

As a conclusion to his abstract (https://wao.confex.com/wao/sib2013/webprogram/Paper5709.html), Dr. Sampson stated that “based on pre-clinical and early clinical trials, EPIT may provide a safe and effective form of immunotherapy to treat patients with food allergy.”

Dr. Pierre-Henri Benhamou, Chairman & CEO of DBV Technologies, said: “We are delighted that our Epicutaneous Immunotherapy was selected and presented during this WAO meeting in Chicago. DBV Technologies keeps on exploring the EPIT approach, by methodically rolling out various preclinical and clinical programmes, supported by an impressive Scientific Advisory Board, of which Dr. Sampson is a member. Thanks to this unmatched scientific and clinical activity, DBV Technologies can now open up a decisive new approach to the treatment of food and pediatric allergies – a major public health issue unfortunately constantly growing in prevalence.”

About peanut allergy: a life-threatening allergy for millions of people

In the United States, about 1.1% of the general population, or over 3 million people, is allergic to peanuts. Peanut allergy causes about 100 to 150 deaths per year. This allergy affects both adults and children, and it has been estimated that peanut allergy affects 1.8% of young children in the United Kingdom. The prevalence of peanut allergy in other Western countries (e.g., Canada, France and Spain) has been studied by many researchers and ranges from 0.9% to 1.5%. This allergy is generally considered to be persistent; many studies indicate that fewer than 20% of children will outgrow their peanut allergy. Peanut allergy is more severe than other common food allergies (e.g. milk and egg allergies).

About DBV Technologies

DBV Technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient’s tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company’s significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product’s clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy – a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).

For more information on DBV Technologies, please visit our website: www$dbv-technologies.com

CAUTION: Viaskin® is not approved for sale in the USA.

Forward Looking Statement

The forward-looking statements, objectives and targets contained herein are based on the Company’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Furthermore, the Research and Development process involves several stages each of which involve the substantial risk that the Company may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Company cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. DBV technologies’ business is subject to the risk factors outlined in
its registration documents filed with the French Autorité des Marchés Financiers.

Contacts

David Schilansky  
Chief Financial Officer  
DBV Technologies  
Tél. : +33(0)1 55 42 78 75  
david.schilansky@dbv-technologies.com

NewCap.  
Financial Communication and investor relations  
Emmanuel Huynh / Valentine Brouchot  
Tél. : +33(0)1 44 71 94 94  
dbv@newcap.fr

Alan S. Roemer  
U.S. Investor Relations  
The Trout Group  
Tél. : +1 646 378-2945  
aroemer@troutgroup.com

Ronald Trahan, APR  
Press relations  
Ronald Trahan  
Tél. : +1 508 359 4005  
rctrahan@ronaldtrahan.com

# # # # #